Home › Cancro pancreatico › Texas
Studi clinici su Cancro pancreatico nello stato di Texas
78 studi su Cancro pancreatico cercano partecipanti presso sedi nello stato di Texas.
Città nello stato di Texas
- Houston61 studi
- San Antonio31 studi
- Dallas22 studi
- Irving7 studi
- Austin7 studi
- League City3 studi
- The Woodlands3 studi
- Fort Worth3 studi
Testo ufficiale dello studio (inglese)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Texas MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics (START), San Antonio
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06465069Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Texas Oncology - West Texas, Abilene
- Texas Oncology - Austin, Austin
- Texas Oncology - San Antonio, San Antonio
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT07562152Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
- UT MD Anderson Cancer Center, Houston
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05372614A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06760819A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06172478A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center - Conroe, Conroe
- University of Texas MD Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
- e altri 3
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07090499A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, Houston
- PHN-012-001 Site, San Antonio
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT07127874Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
- University of Texas MD Anderson Cancer Center, Houston
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07621718A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- START Dallas Fort Worth, Fort Worth
- MD Anderson, Houston
- NEXT Oncology Houston, Houston
- e altri 1
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07277413DESTINY-PANTUMOUR04
- Research Site, Dallas
In reclutamentoStudio osservazionale
Età da 18 a 130 · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07124000A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
- University of Texas Southwestern Medical Center-William P. Clements Jr. University Hospital, Dallas
- University of Texas Southwestern Medical Center-Zale Lipshy University Hospital, Dallas
- e altri 3
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06989437Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
- Texas Oncology - DFW, Dallas
- University of Texas, Southwestern Medical Center, Dallas
- University of Texas MD Anderson Cancer Center, Houston
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07252232Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- MD Anderson, Houston
- NEXT Dallas, Irving
- NEXT Oncology San Antonio, San Antonio
- e altri 1
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06128551A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
- UT Southwestern Medical Center at Dallas, Dallas
- Houston Methodist Office of Graduate - Houston Methodist Neal Cancer Center at Texas Medical Center, Houston
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07409272Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Baylor College of Medicine, Houston
- The University of Texas MD Anderson Cancer Center, Houston
- NEXT Oncology Dallas, Irving
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06445062A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
- Investigative Site US067, Dallas
- Investigative Site US062, Denison
- Investigative Site US011, Houston
- e altri 2
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07522073Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
- The University of Texas MD Anderson Cancer Center, Houston
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT06271291A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT07629960Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- NEXT - Dallas, Dallas
- NEXT, San Antonio
- START - San Antonio, San Antonio
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT07349537A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Local Institution - 0085, Houston
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT07492680CREO - Microwave Ablation Feasibility Study
- Memorial Hermann-Texas Medical Center, Houston
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT07817147Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
- University of Texas Southwestern/Children's Medical Center, Dallas
- M D Anderson Cancer Center, Houston
- Texas Children's Hospital, Houston
- e altri 1
In reclutamentoStudio osservazionale
Fino a 17 anni · Tutti i sessi · Aggiornato il 11 set 2026 · NCT06651580A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
- UT MD Anderson, Houston
- NEXT Oncology, San Antonio
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2026 · NCT06440005A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- The University of Texas - MD Anderson Cancer Center, Houston
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT06400472Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
In reclutamentoStudio osservazionale
Età da 50 a 75 · Tutti i sessi · Aggiornato il 4 set 2026 · NCT04239573iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- M D Anderson Cancer Center, Houston
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT03608631A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
- START Dallas, Fort Worth
- MD Anderson Cancer Center, Houston
- START- San Antonio, San Antonio
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT07644559PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
- University of Texas Southwestern Medical Center, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 set 2026 · NCT06673017Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
- Ut Southwestern, Dallas
- Texas Oncology - DFW, Fort Worth
- MDACC, Houston
- e altri 2
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 set 2026 · NCT05245500Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- START San Antonio, San Antonio
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 27 ago 2026 · NCT06582017Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
- Texas Oncology, Houston
- Baylor College of Medicine, Houston
- University Cancer and Diagnostic, Houston
In reclutamento
Età da 18 a 120 · Tutti i sessi · Aggiornato il 27 ago 2026 · NCT06698458Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
- Baylor College of Medicine Medical Center - McNair Campus, Houston
- Baylor St. Lukes Medical Center, Houston
- Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 26 ago 2026 · NCT04157127Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
- Houston Methodist San Jacinto Hospital, Baytown
- UT MD Anderson - The Woodlands, Conroe
- Houston Methodist Cypress Hospital, Cypress
- e altri 16
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT06958328A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
- Oncology Consultants, P.A., Houston
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT07157033A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- NEXT Dallas, Irving
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 ago 2026 · NCT07066657Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, Houston
- Research Site, San Antonio
In reclutamentoFase 1/2
Età da 18 a 130 · Tutti i sessi · Aggiornato il 12 ago 2026 · NCT05417594A Study of MGC026 in Participants With Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 ago 2026 · NCT06242470A Study of DM002 in Patients With Advanced Solid Tumors
- The University of Texas, MD Anderson Cancer Center, Houston
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 7 ago 2026 · NCT06751329Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
- Excel Diagnostics & Nuclear Oncology Center, Houston
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 7 ago 2026 · NCT07733674IDOV-Immune for Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics, San Antonio
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 ago 2026 · NCT06910657Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.